24 October 2024: Newly published findings from the TROG 14.02 RAIDER trial offer promise for the use of complex adaptive...
Read more
Menu
Trans Tasman Radiation Oncology Group is one of the largest cancer clinical trials groups in Australia and New Zealand.
Over three decades, the Trans Tasman Radiation Oncology Group (TROG) has facilitated more than 100 clinical trials that have helped improve the quality of life and treatment options for almost 15,000 volunteer cancer patients.
During that time, the prognosis of cancer patients has improved considerably. In the 1980s the cancer survival rate was less than 50 per cent. Today, for some cancers, the survival rate is as high as 90 per cent.
TROG Cancer Research is focused on radiation treatment, for the many types of cancers it can treat.
Our upcoming, current, and past clinical trials have investigated the effectiveness of radiation therapy in treating the following groups of cancers. Our members have also investigated the impact of radiation therapy on symptom management and palliative care.
View the successful TROG trial results and outcomes of all bladder, kidney and prostate cancers trials here.
Discover our research within bone cancers and the treatments and trials our team have been apart of.
Interested in learning more about how TROG contributes to brain and central nervous system cancer results?
See how we contribute to a greater understanding of effective treatments for breast cancer patients.
Understand how TROG contributes to gastrointestinal cancer research and their global results here.
View the successful TROG trial results and outcomes of all gynaecological cancer trials here.
Eager to more about how TROG contributes to head and neck cancer treatments? Click here.
Discover our research within lung cancer and the treatments and trials our team have been apart of.
See how we contribute to a broader understanding of effective treatments for lymphoma cancer patients.
Explore our current oesophageal cancer trials and the impact of TROG.
View the successful TROG trial results and outcomes of all pancreatic cancer trials here.
Understand the degree in which TROG contributes to skin cancer research and global results here.
The radiation medicine research team is multidisciplinary, working with TROG Cancer Research members, hospitals, universities, and trial coordinating centres to advance vital cancer research for the community.
Translational research is a key strength of Trans-Tasman Radiation Oncology Group (TROG). Initiatives that were once a part of research projects conducted in laboratories and clinics throughout Australasia are now incorporated into standard care in a clinical setting.
Patients who choose to be part of a cancer clinical trial can be assured that patient safety and radiation therapy protocol compliance is stringently monitored under the TROG Cancer Research Radiation Therapy Quality Assurance (RTQA) program.
As new technologies and techniques are incorporated into radiation therapy treatment, RTQA develops robust radiation therapy planning, delivery, and quality assurance guidelines that ensure compliance and trial quality.
We invite you to explore the cancer clinical trials projects and people leading the fight to cure all cancers with one treatment.
Full membership to the Trans-Tasman Radiation Oncology Group (TROG) is open to anyone qualified in their discipline. This includes Radiation Oncologists, Medical Oncologists, Radiation Therapists, Medical Physicists, Statisticians, Data Managers, Nurses, and Surgeons.
Affiliate membership is also available to anyone qualified or training in a radiation therapy-related discipline. For full details, visit our membership page.
24 October 2024: Newly published findings from the TROG 14.02 RAIDER trial offer promise for the use of complex adaptive...
Read more23 October 2024: TROG Cancer Research is thrilled to be among 14 clinical trial groups awarded new Cancer Australia funding...
Read more15 October 2024: TROG Cancer Research has made a commitment to embracing the principles of diversity, equity and inclusion (DEI)...
Read more
For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.
Latest News
Keep up to date with TROG news, subscribe to our community newsletter.
ABN: 45 132 672 292
